Cancer
Conditions
Keywords
ErbB2+ breast cancer, ErbB2 treatment, brain metastases
Brief summary
This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region. We aim to identify approximately 300 erbB2+ breast cancer patients with brain metastases diagnosed between 2006-2008 in 6 countries. Medical records will be analyzed to determine the treatment pattern for brain metastases, including anti-erbB2 therapy. Additional objectives are to understand the impact of anti-erbB2 therapy on survival after brain metastases and to investigate the relationship between anti-erbB2 therapy for brain metastases and: 1) the time interval between diagnosis of erb2+ breast cancer and brain metastasis, and 2) the occurrence of brain metastasis as the first site of disease progression.
Interventions
DRUGAnti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer
Trastuzumab or Lapatinib
Sponsors
GlaxoSmithKline
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
1. Female patients diagnosed with erbB2+ breast cancer. ErbB2 positivity will be as determined by respective institutional standards, and will be based on medical history only. 2. Brain metastasis diagnosis made between January 2006 - December 2008.
Exclusion criteria
1. Women who have another primary cancer diagnosed between the time of breast cancer diagnosis and brain metastasis.. 2. Patient has leptomeningeal metastases only without parenchymal brain involvement (since this pattern of the disease requires a different treatment approach.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To describe the treatment pattern of brain metastasis in ErbB2 over-expressing breast cancer in Asia Pacific countries. | Time (in months) from date of first diagnosis of brain metastasis through to death or end of study period |
Secondary
| Measure | Time frame |
|---|---|
| To describe the survival of ErbB2 over-expressing breast cancer patients with brain metastasis after diagnosis of brain metastasis in relation to the receipt of anti-erbB2 therapy. | Time (in months) from date of first diagnosis of brain metastasis through to death or end of study period |
| Describe association between usage of anti-erbB2 therapy (before brain metastasis) & 1) time interval from diagnosis of erbB2+ breast cancer to occurrence of brain metastasis and 2) occurrence of brain metastasis as the first site of disease progression | Time (in month) between the date of diagnosis of erbB2+ breast cancer and date of first diagnosis of brain metastasis |
Countries
Philippines, Singapore, Thailand
Outcome results
None listed